Dermatology

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

Our top 5 headlines included a new approval for atopic dermatitis, expert consensus on anaphylaxis care, and the end of the semaglutide shortage.

Investigators in China developed a patch test designed for hair care products tailored to clinical needs such as those of patients with conditions like alopecia areata.

These data suggest therapeutic modulation of IL-23 inhibitors for psoriasis in those who have shown stability may be a legitimate strategy to ensure efficacy and safety.

A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.

In new data to be presented at AAAAI, the therapy was well-tolerated in people as young as 2 years old.

These data were the result of a new network meta-analysis looking specifically at children with eczema, highlighting the hierarchy of effectiveness among systemic drugs.

By week 52, remibrutinib and placebo-to-remibrutinib groups had similar levels of urticaria control.

Alpyn’s Investigational New Drug application’s clearance by the FDA for the new Zabalafin Hydrogel for atopic dermatitis follows positive phase 2a clinical findings.

This genome-wide meta-analysis demonstrated that changes in 2 parts of the genome both work to influence patients’ risk of frontal fibrosing alopecia (FFA).

In this feature, 3 experts highlight their own research on new technological advances and their views on the benefits and drawbacks of artificial intelligence in dermatology.

This analysis highlights the major risk factors resulting in limited use of oral JAKi for patients with hidradenitis suppurativa, including smoking, obesity, hypertension, and age.

Data from 3 pooled phase 3 studies in children, adolescents, and adults will be presented at the AAAI/WAO Joint Congress.

The February 18, 2025 SOCS News Update highlights SOCS mentorship opportunities as well as the importance of mentors and role models.

A study found many patients with chronic spontaneous urticaria need add-on or higher-dose therapies, revealing gaps in treatment. Findings will be presented at AAAAI 2025.

The FDA decision to approve the supplemental biologics license application for dupilumab (Dupixent) follows recent pivotal clinical trial data assessing 106 patients.

This analysis highlights the efficacy and safety of abrocitinib among patients with atopic dermatitis in China, as well as the medication’s impact on patients’ blood biomarkers.

At week 12, a higher proportion of participants on rilzabrutinib 1200mg a day (60.9%) achieved AAS7 scores of 0 than placebo-treated participants (30.8%).

These findings from the POETYK-PSO long-term extension trial point to a lack of new safety concerns in the first 5 years of using deucravacitinib for psoriasis.

In this episode, James Q. Del Rosso, DO, joins The Medical Sisterhood for a conversation about empowerment and the benefits of female role models.

Infants who develop atopic dermatitis show early cheek skin barrier dysfunction with delayed FLG processing, low ceramides, and high IL-18. The study will be presented at AAAAI 2025.

At 6 months, baseline monthly rates of 0.45 for mild, 1.54 for moderate, and 0.14 for severe attacks were reduced to 0.10, 0.08, and 0.00, respectively.

These data expand upon existing literature on pediatric HS and racial differences among patients based on management, presentation, and severity.

Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

These data highlight deucravacitinib’s impact among patients with psoriasis who are biologic- and apremilast-naive and those with prior histories with these treatments.